{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:35:40Z","timestamp":1791081340682,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoantibodies against factor VIII (FVIII) are rare but can cause life-threatening bleeding requiring costly factor replacement and prolonged immunosuppression. We report 4 consecutively treated patients whose acquired FVIII inhibitors responded rapidly to immunosuppressive regimens that included rituximab, a monoclonal antibody against CD20+ B cells. Three patients had spontaneously occurring inhibitors. The fourth, a patient with mild hemophilia A, developed both an autoantibody and an alloantibody following recombinant FVIII treatment. Pretreatment FVIII activities ranged from less than 1% to 4% and inhibitor titers from 5 to 60 Bethesda units (BU). One patient with polymyalgia rheumatica who developed the inhibitor while receiving prednisone responded to single agent rituximab. The hemophilia patient had rapid resolution of the autoantibody, whereas the alloantibody persisted for months. Responses continue off treatment from more than 7 to more than 12 months. This report adds to the growing evidence that rituximab has efficacy in immune disorders resulting from autoantibody formation.<\/jats:p>","DOI":"10.1182\/blood-2002-03-0765","type":"journal-article","created":{"date-parts":[[2002,10,16]],"date-time":"2002-10-16T19:03:08Z","timestamp":1034794988000},"page":"3426-3428","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":178,"title":["Rituximab in the treatment of acquired factor VIII inhibitors"],"prefix":"10.1182","volume":"100","author":[{"given":"Adrian","family":"Wiestner","sequence":"first","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hearn J.","family":"Cho","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Asch","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Michelis","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A.","family":"Zeller","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellinor I. B.","family":"Peerschke","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette B.","family":"Weksler","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine P.","family":"Schechter","sequence":"additional","affiliation":[{"name":"From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Weill Medical College, Cornell University, New York, NY; Hackensack University Medical Center, Hackensack, NJ; and Veterans Affairs Medical Center and George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111617433035000_B1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.","volume":"45","author":"Green","year":"1981","journal-title":"Thromb Haemost."},{"key":"2019111617433035000_B2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1055\/s-0038-1665434","article-title":"The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.","volume":"78","author":"Hay","year":"1997","journal-title":"Thromb Haemost."},{"key":"2019111617433035000_B3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.V81.6.1513.1513","article-title":"Use of porcine factor VIII in the treatment of patients with acquired hemophilia.","volume":"81","author":"Morrison","year":"1993","journal-title":"Blood."},{"key":"2019111617433035000_B4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0950-3536(98)80049-8","article-title":"Acquired haemophilia.","volume":"11","author":"Hay","year":"1998","journal-title":"Baillieres Clin Haematol."},{"key":"2019111617433035000_B5","first-page":"33","article-title":"Factor VIII inhibitors\u2014an algorithmic approach to treatment.","volume":"31","author":"Kessler","year":"1994","journal-title":"Semin Hematol."},{"key":"2019111617433035000_B6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00062752-200011000-00015","article-title":"New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.","volume":"7","author":"Kessler","year":"2000","journal-title":"Curr Opin Hematol."},{"key":"2019111617433035000_B7","first-page":"28","article-title":"Immunosuppression of factor VIII inhibitors in nonhemophilic patients.","volume":"30","author":"Green","year":"1993","journal-title":"Semin Hematol."},{"key":"2019111617433035000_B8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.1981.00635.x","article-title":"Corticosteroid therapy for acquired F VIII:C inhibitors.","volume":"48","author":"Spero","year":"1981","journal-title":"Br J Haematol."},{"key":"2019111617433035000_B9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0038-1649664","article-title":"A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies.","volume":"70","author":"Green","year":"1993","journal-title":"Thromb Haemost."},{"key":"2019111617433035000_B10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/0003-4819-110-10-774","article-title":"Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor.","volume":"110","author":"Lian","year":"1989","journal-title":"Ann Intern Med."},{"key":"2019111617433035000_B11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7326\/0003-4819-127-3-199708010-00005","article-title":"Successful treatment of acquired hemophilia with oral immunosuppressive therapy.","volume":"127","author":"Shaffer","year":"1997","journal-title":"Ann Intern Med."},{"key":"2019111617433035000_B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<87::AID-AJH17>3.0.CO;2-6","article-title":"Successful treatment of acquired factor VIII inhibitors with cyclosporin.","volume":"57","author":"Brox","year":"1998","journal-title":"Am J Hematol."},{"key":"2019111617433035000_B13","first-page":"323","article-title":"A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporine.","volume":"20","author":"Hart","year":"1988","journal-title":"Transplant Proc."},{"key":"2019111617433035000_B14","first-page":"79","article-title":"The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.","volume":"27","author":"Treon","year":"2000","journal-title":"Semin Oncol."},{"key":"2019111617433035000_B15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood."},{"key":"2019111617433035000_B16","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab.","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet."},{"key":"2019111617433035000_B17","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors [abstract].","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh."},{"key":"2019111617433035000_B18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy.","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch Intern Med."},{"key":"2019111617433035000_B19","first-page":"533a","article-title":"Treatment of acquired factor VIII deficiency with rituximab [abstract].","volume":"98","author":"Karwal","year":"2001","journal-title":"Blood."},{"key":"2019111617433035000_B20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.","volume":"344","author":"Dervite","year":"2001","journal-title":"N Engl J Med."},{"key":"2019111617433035000_B21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab.","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood."},{"key":"2019111617433035000_B22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","article-title":"Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder [letter].","volume":"345","author":"Suzan","year":"2001","journal-title":"N Engl J Med."},{"key":"2019111617433035000_B23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1055\/s-0037-1615061","article-title":"Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.","volume":"79","author":"Hay","year":"1998","journal-title":"Thromb Haemost."},{"key":"2019111617433035000_B24","first-page":"892","article-title":"Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab.","volume":"60","author":"Stewart","year":"2001","journal-title":"Ann Rheum Dis."},{"key":"2019111617433035000_B25","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/9\/3426\/1258975\/h82102003426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/9\/3426\/1258975\/h82102003426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T17:44:01Z","timestamp":1573926241000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/9\/3426\/16423\/Rituximab-in-the-treatment-of-acquired-factor-VIII"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-03-0765","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}